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Scrapie prions: a three-dimensional model of an 
infectious fragment
Ziwei Huang1,2†, Stanley B Prusiner2,3 and Fred E Cohen1,3,4
Background: A conformational change seems to represent the major difference
between the scrapie prion protein (PrPSc) and its normal cellular isoform (PrPC).
We recently proposed a set of four helix bundle models for the three-dimensional
structure of PrPC that are consistent with a variety of spectroscopic and genetic
data.
Results: We report a plausible model for the three-dimensional structure of a
biologically important fragment of PrPSc. The model of residues 108–218 was
constructed by an approach that combines computational techniques and
experimental data. The proposed structures of this fragment of PrPSc display a
four-stranded β-sheet covered on one face by two α-helices. Residues
implicated in the prion species barrier are found to cluster on the solvent-
accessible surface of the β-sheet of one of the models. This interface could
provide a structural template that would assist the conversion of PrPC to PrPSc
and hence direct prion propagation.
Conclusions: Molecular models of the PrP isoforms should prove very useful in
developing structural hypotheses about the process by which PrPC is
transformed into PrPSc, the mechanisms by which PrP gene mutations give rise
to the inherited human prion diseases, and the species barrier that seems to
protect humans from animal prions. It seems likely that PrPC represents a
kinetically trapped intermediate in PrP folding.
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Introduction and background
Prions cause a group of human and animal neurodegenera-
tive diseases that are now classified together because their
etiology and pathogenesis involve modification of the
prion protein (PrP) [1,2]. Prion diseases are manifest as
infectious, genetic and sporadic disorders. These diseases
can be transmitted among mammals by the infectious par-
ticle designated `prion’ [3]. Despite intensive searches
over the past three decades, no nucleic acid has been
found within prions [4–7]; yet, a modified isoform of the
host-encoded PrP, designated PrPSc, is essential for infec-
tivity [1,8–11]. In fact, considerable experimental data
argue that prions are composed exclusively of PrPSc. Ear-
lier terms used to describe the prion diseases include
transmissible encephalopathies, spongiform encephalo-
pathies and slow virus diseases [12–14].
The quartet of human prion diseases are frequently
referred to as kuru, Creutzfeldt–Jakob disease (CJD),
Gerstmann–Sträussler–Scheinker (GSS) disease and fatal
familial insomnia (FFI). Kuru was the first of the human
prion diseases to be transmitted to experimental animals
and it has often been suggested that kuru spread among
the Fore people of Papua New Guinea by ritualistic can-
nibalism [13,15]. The experimental and presumed
human to human transmission of kuru led to the belief
that prion diseases are infectious disorders caused by
unusual viruses similar to those causing scrapie in sheep
and goats. Yet, a paradox was presented by the occur-
rence of CJD in families, first reported almost 70 years
ago [16,17], which appeared to be a genetic disease. The
significance of familial CJD was unappreciated until
mutations were discovered in the protein-coding region
of the PrP gene on the short arm of chromosome 20
[18–20]. The earlier finding that brain extracts from
patients who had died of familial prion diseases 
inoculated into experimental animals often transmit dis-
ease posed a conundrum that was resolved with the
genetic linkage of these diseases to mutations of the PrP
gene [21–23].
The most common form of prion disease in humans is spo-
radic CJD. Many attempts to show that the sporadic prion
diseases are caused by infection have been unsuccessful
[24–27]. The discovery that inherited prion diseases are
caused by germline mutation of the PrP gene raised the
possibility that sporadic forms of these diseases might
result from a somatic mutation [22]. The discovery that
PrPSc is formed from the cellular isoform of the prion pro-
tein, PrPC, by a posttranslational process [28] and that
overexpression of wildtype PrP transgenes produces
spongiform degeneration and infectivity de novo [29] has
raised the possibility that sporadic prion diseases result
from the spontaneous conversion of PrPC into PrPSc.
The fundamental event in prion diseases seems to be a
conformational change in PrP [30]. All attempts to identify
a posttranslational chemical modification that distin-
guishes PrPSc from PrPC have been unsuccessful to date
[31]. PrPC contains ~45% α-helix and is virtually devoid of
β-sheet [32]. Conversion to PrPSc creates a protein that
contains ~30% α-helix and ~45% β-sheet. The mechanism
by which PrPC is converted into PrPSc remains unknown
but PrPC appears to bind to PrPSc to form an intermediate
complex during the formation of nascent PrPSc. Trans-
genic mouse studies have demonstrated that PrPSc in the
inoculum interacts preferentially with homotypic PrPC
during the propagation of prions [33,34]. 
Elucidating the three-dimensional structure of both PrPC
and PrPSc is central to understanding the molecular mech-
anism of prion diseases. An approximate tertiary structure
of PrPC was proposed recently that is rich in α-helical
structures consistent with available spectroscopic data [35].
As the insoluble aggregated nature of PrPSc complicates X-
ray and NMR studies of its three-dimensional structure,
we have utilized an approach that combines computational
techniques and a synthesis of available data from genetic,
molecular biological, and spectroscopic experiments. Our
approach includes secondary structure prediction, a combi-
natorial search of all plausible arrangements of these sec-
ondary structure elements to form tertiary structures, and
an analysis of the putative tertiary structures to identify
those candidates that are consistent with a variety of pieces
of experimental and theoretical information. In an effort to
simplify this task, we chose to focus on a biologically rele-
vant fragment of PrPSc. PrP includes three regions: an N-
terminal leader sequence (residues 1–23); the octarepeats,
a sequentially regular region with a pattern of amino acid
side chains that is not easily related to other known peri-
odic structures (residues 24–90); and the 27–30 kDa infec-
tious fragment, PrP 27–30, that remains after proteinase K
digestion of PrPSc (residues 90–240), which includes two
potential glycosylation sites and a glycophosphoinositol
anchor near the C terminus. Although polymorphisms in
the octarepeat region have been associated with inherited
disease, a comparison of the octarepeat regions of primate
PrP sequences demonstrate that these can be normal poly-
morphisms [36]. We have chosen to focus on the third
region because of the connection to infectivity, the fact
that the vast majority of disease-associated mutations and
disease-modifying polymorphisms occur in this region, and
because of the demonstration that peptides chosen from
this region (e.g. 90–145 and 108–141) undergo an α-helix
to β-structure transition in vitro that is reminiscent of the
conversion of PrPC into PrPSc [37]. The fact that a Japan-
ese patient with a missense mutation at codon 145 devel-
oped a neurodegenerative illness argues that the crux of
the conformational change must occur between residues
90 and 145 [38].
Results and discussion
The secondary structure of PrPSc was predicted with spe-
cific biases introduced to accommodate data from circular
dichroism (CD) and Fourier transform infrared (FTIR)
spectroscopic experiments. CD and FTIR studies indicate
that approximately half of the α-helical structure in PrPC
is converted into β-sheet in PrPSc [32,39]. Results from
various secondary structure prediction methods and spec-
troscopic studies of PrP peptide fragments argue that the
four structural regions corresponding to the helices in
PrPC are most likely to undergo a conformational change
from α-helix to β-sheet in PrPSc [35,40]. These findings
suggest that two of the four helices of PrPC are converted
into β-sheet structure in PrPSc. We therefore systemati-
cally assigned two of the four putative helical regions to β-
sheet conformations.
The tertiary structures of PrPSc were generated by exam-
ining the plausible hydrophobic packing between sec-
ondary structures. A combinatorial packing approach
developed for α/β proteins [41,42] was employed to pre-
dict tertiary structural models for PrPSc. All possible strand
arrangements and relative pairing of the component
strands to form a β-sheet were studied. Briefly, each of the
four strands could occupy one of 4! orders (1234, 2143,
etc.) and there are two possible orientations for each β-
strand. Strand alignments are shifted to create four distinct
hydrogen bonding patterns for each strand. Thus, a large
number of structures are generated with unique strand
topologies and hydrogen bonding patterns, including par-
allel, antiparallel, and mixed β-sheets. The separation
between the axes of the β-strands was 4.25 Å to facilitate
hydrogen bonding and the angle between neighboring
strands was –20° to create the twisted β-sheet that is com-
monly observed in protein structures [41]. The α-helices
were then placed onto the hydrophobic surface of the β-
sheet structure so that a constellation of non-polar
residues on the surface of each α-helix could interact with
the hydrophobic surface of the β-sheet. Helices were
placed antiparallel to the preceding secondary structure
element 10 Å above the plane of the sheet. This organiza-
tion is typical of α/β and α+β protein structures. Structures
were eliminated if their β-sheets failed to create a
hydrophobic surface suitable for subsequent helix–sheet
packing or if the β-sheet topology created steric problems
for the loops that would ultimately join the β-strands. For
example, if two six-residue strands were joined by a four-
residue turn, they could not run parallel to one another in
a β-sheet without breaking the chain. Structures were also
eliminated if they failed to form the experimentally deter-
mined disulfide bond between Cys179 and Cys214 [43].
From an initial list of ~106 structures, six families of struc-
tures were considered viable (Fig. 1). These six structural
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models were validated by a three-dimensional profile
method [44]. The profile scores are presented in Table 1.
Although self-profiling methods cannot guarantee the
accuracy of a given model structure, they are useful in
identifying errant folds and alignments.
The generated three-dimensional model structures were
examined in order to select the models that were most
consistent with experimental data. Genetic experiments
indicated that a specific interaction between PrPSc and
PrPC is important for prion propagation [33,34]. A small
number of residues were found to be central to the prion
species barrier, a phenomenon that depends upon the
homotypic interaction of PrPSc with PrPC [36]. Each of the
six plausible structures (Fig. 1) was analyzed with respect
to the residues implicated in the PrPSc–PrPC interaction
(Asn108, Met112, Met129, and Ala133). One of the models
was most intriguing with respect to the spatial clustering of
these residues. As shown in Figure 2a, this model displays
a four-stranded β-sheet with one face covered by two α-
helices. The β-strand arrangement in the β-sheet is similar
to that observed in the structure of the immunoglobulin-
binding domain of protein G (GB1) [45], and the overall
packing topology between the β-sheet and two α-helices is
similar to that observed in the structure of the RNA-bind-
ing domain of the human heterogeneous nuclear ribo-
nucleoprotein (hnRNP) C protein [46]. The four residues
implicated in the species barrier, and thus the PrPSc–PrPC
interaction, are clustered on the solvent-accessible surface
of the β-sheet of model II. In addition, a number of hydro-
phobic side chains are located on this surface. These
observations suggest that the solvent-accessible surface of
the β-sheet provides a plausible interface for a specific
interaction of PrPSc with PrPC that could promote the con-
formational change of PrPC to PrPSc. Mutations at this
interface would alter the incubation times associated with
different inocula of prions in different hosts. This suggests
that the prion species barrier results from the changes in
the conformation and stability of the PrPSc–PrPC complex.
Transgenic experiments are underway to create new and
abrogate existing species barriers based on this model.
Although we currently favor model II of PrPSc, it is impor-
tant to remember that each model is emblematic of a fam-
ily of protein topologies, and that formal experimental or
theoretical constraints prevent one from excluding the
other five plausible models. 
The model of the PrPSc–PrPC complex may provide a
structural basis for observations from genetic experiments.
Transgenic studies of the transmission of prions from Syr-
ian hamster to mouse indicate that five residues (109, 112,
138, 154, and 169) are important for the homophilic inter-
action between PrPSc molecules within the inoculated
prion and PrPC synthesized by the host [34]. It is interest-
ing to note that three of these five residues (109, 112, and
138) are located at or near the hypothesized PrPSc–PrPC
interface (Fig. 2a), while the remaining two residues (154
and 169) are located in the S2b–H3 loop connecting the
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Figure 1
Schematic drawings of the six plausible
structures of PrPSc. These structural models
were selected from an initial list of ~106
structures. β-strands are represented by an
arrow and α-helices by a rectangle. Helices
are numbered A2 (129–141), A3 (178–191)
and A4 (202–218), and strands are labeled
S1a, S1b, S2a, S2b, S4a, and S4b. See text for











































fourth strand in the β-sheet and helix 3. This suggests
that, in addition to the β-sheet being the primary site for
interaction, the loop following the β-sheet might also be
involved in molecular recognition during prion replication.
This would be consistent with model II for PrPSc, in which
this conformationally flexible loop could come into contact
with PrPC during the formation of the PrPSc–PrPC com-
plex (Fig. 2a). Such a model also provides a consistent
explanation for the recent studies of the transmission of
CJD from humans to transgenic mice. Mice expressing a
chimeric PrP gene containing nine substitutions were sus-
ceptible to prions from CJD patients [47]. Eight of these
nine substitutions are located either in the putative β-
sheet region of model II or the S2b–H3 loop region of the
PrPSc model. Analyses of PrP genes among various pri-
mates indicated that mutations at residue 177 and a poly-
morphism at residue 168 are implicated in the prion
species barrier [36,48]. These findings provide further evi-
dence for the possible structural or functional role of the
putative S2b–H3 loop.
Recently, other authors raised the issue that overall
sequence homology might not be a determining influence
for prion transmissibility [49]. This hypothesis was based
on the finding that, despite the sequence similarity to
humans, Old World rhesus monkeys exhibit a lower trans-
mission rate of human prions than either of the more evo-
lutionarily distal New World spider or squirrel monkeys.
Examination of these results in the context of the pro-
posed model for the PrPSc–PrPC interaction reveals that
PrP from Old World rhesus monkey contains a substitu-
tion at codon 108 (Asn→Ser) at the solvent-accessible sur-
face of the putative β-sheet, a primary site of PrPSc–PrPC
interface (Fig. 2a). This substitution might decrease the
stability of the PrPSc–PrPC complex and hence lower the
transmission rate of human prions. Thus, our structural
model for prion replication suggests that the sequence, or
more precisely structural similarity, at the PrPSc–PrPC
interface, rather than the overall sequence homology, may
be the major determinant for prion transmissibility.
The proposed structural model of PrPSc is consistent with
the mutation data in familial prion diseases. 18 mutations
in the PrP gene have been identified that segregate with
the inherited prion diseases [19,50]. Although octarepeat
inserts at codons 67, 75, or 83 of the N-terminal region are
either genetically linked to or associated with familial
CJD, all other disease-associated point mutations occur in
the C-terminal region, in which the β-sheet and α-helical
structures are predicted to occur. As the deletion of the N-
terminal region of PrPSc before residue 90 by limited pro-
teolysis does not alter prion infectivity, this suggests that
the N-terminal region is not required for the propagation
of prions. Point mutations in the C-terminal region may
affect the structure of either PrPC or PrPSc and promote
the conformational change featured in prion diseases. It
was found, for example, that 10 mutations are located
within or near the four putative α-helices and five muta-
tions cluster around a central hydrophobic core that seems
essential for the structural stability of PrPC (Fig. 2b) [35].
It is noted that a nonsense mutation at codon 145 was
found in a Japanese patient dying of CJD [38]. This find-
ing suggests that residues 90–145 might be essential for
the transmission and pathology of prion diseases. This
would be consistent with the proposed model of PrPSc in
which residues 90–145 form the region involved in the
conformational change of two α-helices into a four-
stranded β-sheet. This same region contains the clustering
of residues implicated in the species barrier for prion
transmission (Fig. 2a,b).
The proposed structure of PrPSc is also consistent with
results from structural studies of PrP peptides. Spectro-
scopic studies have shown that the synthetic peptide cor-
responding to residues 109–122 (β-strands 1a and 1b) or
128–141 (β-strands 2a and 2b) of model II of PrPSc adopts
a β-sheet structure and forms amyloid [40,51–53]. Further
structural studies using NMR, FTIR and CD spec-
troscopy of peptides containing both the first and second
putative hairpin structures (e.g. residues 90–145) suggest
that this region can adopt two distinct conformations: one
that contains a pair of helices and a second that is entirely
β-structure [37]. All of these findings seem to be in agree-
ment with the structural features revealed in the models
of PrPSc and PrPC (Fig. 2) and of the formation of a com-
plex between PrPC and PrPSc which seems to occur during
prion propagation.
Conclusions
The models for PrPSc proposed here extend earlier studies
in which computational models were developed for PrPC
[35]. Both the PrPC and PrPSc models were developed
while considering numerous constraints posed by the
physical, genetic and amino acid sequence data available
for these two PrP isoforms. These models should prove
very useful in posing hypotheses about the process by
which PrPC is transformed into PrPSc, the mechanisms by
which PrP gene mutations give rise to the inherited
human prion diseases, and the species barrier that seems
to protect humans from animal prions. In the absence of
more definitive structural information, we believe that
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Table 1. Three-dimensional profiles for the six models of PrPSc.
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Figure 2
Plausible models for the tertiary structures of PrPSc and PrPC. (a) The
proposed three-dimensional structure of PrPSc. This structure was
chosen from the six penultimate models of PrPSc (Fig. 1) because it
appeared to correlate best with genetic data on residues involved in
species barrier. It contains a four-strand mixed β-sheet with two α-
helices packed against one face of the β-sheet. Strands 1a and 1b (in
red) correspond to the helix 1 in PrPC while strands 2a and 2b (in
green) correspond to the helix 2 (b). Helices 3 and 4 in this model
remain unchanged from the PrPC model (b) [35]. Four residues
(Asn108, Met112, Met129, and Ala133) implicated in the species
barrier [36] are shown in the ball-and-stick model. They cluster on the
solvent-accessible surface of the β-sheet, which might provide a
plausible interface for the PrPSc–PrPC interaction. The S2b–H3 loop
connecting the β-sheet and helix 3 is implicated in the species barrier
and is shown in yellow. This conformationally flexible loop could come
into contact with PrPC during the formation of the PrPSc–PrPC
complex. Therefore, the specific molecular recognition during prion
replication might involve both the β-sheet as the primary binding site
and the S2b–H3 loop as an additional site for interaction. (b) The
proposed three-dimensional structure of PrPC [35]. Helix 1 is shown in
red and helix 2 in green. We believe that helices 1 and 2 are converted
into β-sheet structure during the formation of PrPSc (a). The H2–H3
loop corresponding to the S2b–H3 loop in PrPSc is shown in yellow.
Four residues (Asn108, Met112, Met129, and Ala133) implicated in
the species barrier as noted above are shown in the ball-and-stick
model.
these models provide a useful platform for designing
genetic and biophysical experiments to probe the unique
biology of prion diseases.
Materials and methods 
The computational procedures used for the prediction of the three-
dimensional structures of PrPSc involved four major steps: (i) alignment
of a family of homologous sequences, (ii) prediction of secondary struc-
tures, (iii) packing of secondary elements to generate all plausible
tertiary structures, and (iv) selection and refinement of final structural
models. PrP amino acid sequences from one avian and 11 mammalian
sources, including chicken, cow, sheep, rat, mouse, hamster, mink, and
human, were used. The alignment of these sequences was reported
previously [54]. Methods for secondary and tertiary structure prediction
were applied independently to all 12 PrP sequences using the statistical
methods of Chou and Fasman [55] and Garnier et al. [56]; the neural
networks of Kneller et al. [57] and Rost and Sander [58]; and the pat-
tern-based method of Cohen et al. [59]. These methods gave rise to a
consistent prediction of secondary structure location, but a confusing
picture of the local preference forα-helical or β-sheet structure. We sys-
tematically assigned two of the four helical regions in PrPC (Fig. 2b) [35]
to β-sheet conformations and thus obtained six different sets of sec-
ondary structure for PrPSc, i.e. S1a1bS2a2bH3H4, S1a1bH2S3a3bH4,
S1a1bH2H3S4a4b, H1S2a2bS3a3bH4, H1S2a2bH3S4a4b, and H1H2S3a3bS4a4b.
The boundaries of the β-strands and the β-turns of the hairpins were
predicted using a turn-prediction algorithm for α/β proteins [59]. The
predicted boundaries of the plausible β-strands in PrPSc are
Asn108–Ala113 for S1a, Ala116–Val122 for S1b, Tyr128–Ser135 for
S2a, Ile138–Asp144 for S2b, Asp178–Ile184 for  S3a, His187–Thr191
for S3b, Asp202–Val210 for S4a, and Met213–Tyr218 for  S4b. The pre-
dicted boundaries of the α-helices in PrPSc remain unchanged from the
PrPC model (Met109–Val122 for H1,  Met129–Phe141 for H2,
Asp178–Thr191 for H3, and  Asp202–Tyr218 for H4) [35]. Thus, the
models attempt to describe the structure for the 111-residue PrP frag-
ment from residue 108 to residue 218. The predicted secondary struc-
ture corresponds to 64% of the fragment for which 36% is β-structure
(24% intramolecular hydrogen bonds within a PrPSc monomer and
~12% intermolecular hydrogen bonds between β-strands in PrPSc
monomers that form a multimeric state) and 28% is α-helical. These fig-
ures modestly underestimate the values expected from the FTIR studies
and could easily reach the experimental values if the extent of the inter-
molecular hydrogen bonding is larger. The tertiary structures of PrPSc
were generated by examining the plausible hydrophobic packing
between secondary structure elements [41]. Specifically, we sought β-
sheets that created an appropriate hydrophobic surface to support
helix–sheet packing and identified hydrophobic clusters on the surfaces
of putative α-helices to interact with the hydrophobic regions of the β-
sheet. Finally, a series of experimental and theoretical constraints were
applied to select plausible structural models. For example, the existence
of a disulfide bridge between residues 179 and 214 constrains the sep-
aration of the predicted locations for the α and β carbons for these two
residues. Also, the separation between the end of one piece of sec-
ondary structure and the beginning of the next should not exceed a
length that could be spanned by the intervening residues.
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Corrigendum
Scrapie prions: a three-dimensional model of an infectious fragment
Ziwei Huang, Stanley B Prusiner and Fred E Cohen
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In this Research Paper, some numerical errors have been
made in the labeling of certain amino acids in the
sequence of the Syrian hamster prion protein. These are
summarized below.
Page 14, paragraph 3, line 19: the N-terminal leader
sequence should be 1–22 (not 1–23).
Page 14, paragraph 3, line 22: the N-terminal region
cleaved by proteolysis should be 23–89 (not 24–90).
Page 14, paragraph 3, line 24: the C terminus of PrP 27–30
should be 231 (not 240).
Page 14, paragraph 3, line 35: the second -helical peptide
should be 109–141 (not 108–141).
Page 15, paragraph 3, lines 4/5: residues described as
being important for homophilic interactions should be
109, 112, 139, 155, and 170 (not 109, 112, 138, 154, and
169).
Page 16, paragraph 1, line 16: mutations should be at
residue 178 (not 177).
Page 16, paragraph 4, line 5: the synthetic peptide (-
strands 2a and 2b) should be 129–141 (not 128–141).
In addition, some of the helices in Figure 1 (page 15) have
been labeled wrongly. 
Model IV: should show A2 and A3 (not A3 and A4). 
Model V: should show A3 and A2 (not A3 and A4). 
Model VI: should show A4 and A2 (not A3 and A4). 
The corrected version of the figure is shown below.
Figure 1
Schematic drawings of the six plausible
structures of PrPSc. These structural models
were selected from an initial list of ~106
structures. β-strands are represented by an
arrow and α-helices by a rectangle. Helices
are numbered A2 (129–141), A3 (178–191)
and A4 (202–218), and strands are labeled
S1a, S1b, S2a, S2b, S4a, and S4b. See text for
strand N and C termini.
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